A phase I/II study of the investigational drug alisertib in combination with abiraterone and prednisone (AP) for patients with metastatic castration-resistant prostate cancer (mCRPC) progressing on abiraterone

Authors

• William Kelly

Publication/Presentation Date

1-2016

Volume

34

Issue

2

Published In/Presented At

DOI: 10.1200/jco.2016.34.2_suppl.311

Disciplines

Business Administration, Management, and Operations | Health and Medical Administration | Management Sciences and Quantitative Methods

Department(s)

Administration and Leadership

Document Type

Article